Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 15/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | ADK | P55263 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27436588 | 0.89 | SLC29A1 (0.66) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27427587 | 0.87 | SLC29A1 (0.76) | SLC29A1STAT6ADK | |
| SCHEMBL27424030 | 0.85 | SLC29A1 (0.78) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27425247 | 0.85 | SLC29A1 (0.65) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27424704 | 0.83 | SLC29A1 (0.64) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27434472 | 0.82 | SLC29A1 (0.59) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27431355 | 0.82 | SLC29A1 (0.59) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27430269 | 0.81 | SLC29A1 (0.57) | SLC29A1STAT6TP53CYP3A4HIF1A | |
| SCHEMBL27431908 | 0.80 | SLC29A1 (0.57) | SLC29A1STAT6 | |
| SCHEMBL27430365 | 0.80 | SLC29A1 (0.58) | SLC29A1STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |